Form 4 for GNLX GENELUX Corp
Accepted 2025-04-17 00:00:00 ET · period of report 2025-03-14 · accession 0001415889-25-010879 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-04-17 | 2025-03-14 | GNLX | Yu Yong | VP, Clinical Trial Ops | A - Grant | $0.00 | +13.3K | 53.2K | +33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-14 | A | A | 13,350 | $0.00 | 53,219 | D | — | — |